drugset / Trial / NCT07093086
Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label clinical study evaluating the efficacy and safety of CD20/CD19/CD22 multi-targeted chimeric antigen receptor T-cell (CAR-T) injection in patients with relapsed/refractory B-cell lymphoma.
Timeline
- Start
- 2024-11-07
- Primary completion
- 2026-11-30
- Completion
- 2027-01-30
Outcome
Outcome not reported
Stopped: “The primary consideration is the allocation of company resources, and we have no choice but to terminate this research.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19/CD20 dual-targeted CAR-T cells | Cell therapy | — | — |
| Subject | CD19/CD22 dual-targeted CAR-T cells | Cell therapy | — | — |